semaglutide cardiovascular outcomes study 2025 news Canadian Perspectives Whiteboard on the SOUL Trial Recent study finds that semaglutide

Ultra-processed foods 'make you eat more' CNBC (10 January 2026)

Consequently, blood pressure naturally declines

Description Semaglutide is a long-acting GLP-1 receptor agonist engineered to mimic the activity of endogenous glucagon-like peptide-1 while providing substantially longer biological activity than the native hormone

The best long-term strategy: eat healthy, reduce calories moderately, and combine cardio with strength training

In order to make GLP-1 better used in the clinic, drug developers modified its structure and developed a series of GLP-1R agonists (13)

steady state ~45 weeks Best trial result: -24.2% mean body weight at 48 weeks (12mg cohort) Skip the math: our free Peptide Reconstitution Calculator converts any retatrutide vial size and target dose into an exact bacteriostatic water volume